Ophthalmology Times spoke with Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis about how her ...

PYC Therapeutics (ASX:PYC) has jumped on Friday as it moves on the the next stage of its escalating single-dose study using its drug PYC-001 to treat a genetic children’s disease causing blindness.

Researchers are enhancing the best features of AAV capsids and overcoming their limitations to accelerate gene-based therapies.

PYC is looking at therapies across retinitis pigmentosa, polycystic kidney disease, genetic condition Phelan McDermid syndrome, and autosomal dominant optic atrophy, with other undisclosed ...